Business Insider

Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., May 20, 2019 /PRNewswire/ -- Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that positive safety ...
Healio

Nerandomilast reduces FVC decline, has ‘manageable’ adverse events in IPF at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Two differing nerandomilast doses were assessed against ...
Healio

Novel therapy for IPF shows sustained long-term benefits

Please provide your email address to receive an email when new articles are posted on . Patients with idiopathic pulmonary fibrosis treated with a recombinant human pentraxin 2 protein exhibited ...
FierceBiotech

Promedior Announces Initiation of a Phase 2 Clinical Study of PRM-151 in Idiopathic Pulmonary Fibrosis (IPF)

LEXINGTON, Mass.--(BUSINESS WIRE)--Promedior, Inc., today announced the initiation of a Phase 2 trial of PRM-151, a novel investigational anti-fibrotic immunomodulator, in patients with Idiopathic ...
Medindia

Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., March 26, 2019 /PRNewswire/ -- Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that PRM-151, a ...